Depression

Six Years of Data: What the Longest Esketamine Study Shows About Safety

A fair question about any ketamine-based treatment is what happens after years of use. Most studies last weeks. SUSTAIN-3, published in the International Journal of Neuropsychopharmacology in 2025, is the longest look so far.

The study

SUSTAIN-3 followed 1,148 adults with treatment-resistant depression who were taking esketamine (“the S-form of ketamine, sold as Spravato”) nasal spray under supervision. Some stayed in the study for as long as 79 months, about six and a half years, and the average was about three and a half years. In total the study covered 3,777 patient-years of treatment.

Common side effects

The most frequent were headache (36.9%), dizziness (33.9%), nausea (33.6%), dissociation (25.5%), sleepiness (23.1%) and an altered sense of taste (20.2%). These are the same effects seen in shorter studies, and they typically occur on dosing days.

The longer-term concerns

  • Blood pressure: 6.5% of participants had a markedly elevated reading at some point. This was more common in people with a history of hypertension.
  • Bladder health: heavy recreational ketamine use is known to damage the bladder. In this study there were no cases of treatment-related interstitial or ulcerative cystitis.
  • Thinking and memory: cognition stayed stable overall, in adults both under and over 65. Reaction times slowed slightly during maintenance treatment.
  • Misuse: the authors found no evidence of abuse, misuse or withdrawal within the supervised dosing model.
  • Deaths: nine participants (0.8%) died during the study, from causes including COVID-19, pneumonia and one suicide. None was judged to be related to esketamine.

Did the benefit last?

Depression scores improved during the first weeks and then held steady. Remission rates rose from 35.6% at the end of the initial phase to 49.6% at the end of long-term treatment.

Reading it carefully

Three points keep this result in proportion.

  • The study had no comparison group, so it cannot show what would have happened without treatment.
  • People who stay in a study for years tend to be those who are doing well on it, which makes long-term results look better.
  • It tested esketamine nasal spray given in clinics under a safety program. The findings do not automatically carry over to other forms of ketamine, other doses, or unsupervised use.

With those limits stated, SUSTAIN-3 is reassuring on the questions patients ask most often. At medical doses, with supervision, it found no signal of the bladder damage or cognitive decline associated with heavy recreational use.

Sources and further reading

  1. Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study (International Journal of Neuropsychopharmacology, 2025)
  2. SUSTAIN-3 (PubMed record)

This article is for education only and is not medical advice. Talk with a licensed provider about whether any treatment is right for you.

Free ConsultationSchedule
Online
Talk to ProviderCall us